Immuno-Designed starts IDD-3 Phase II

Immuno-Designed Molecules (Paris, France) began Phase II testing of its IDD-3 autologous dendritic cells loaded with tumor antigens from cancer cell line extracts in 12-17 patients with malignant mela...